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Center Heerlen, Heerlen, 4Catharina Hospital Eindhoven, Eindhoven, The Netherlands; and 5University
Hospitals Leuven, Leuven, BelgiumPurpose. To review our experience of endovascular treatment of aorto-enteric fistula (AEF).
Methods. Between March 1999 and March 2005, 15 patients in five university and teaching hospitals in Belgium and The
Netherlands were treated for AEF by endovascular repair. Twelve (80%) were male. The mean age was 67 years. Thirteen
(87%) had had previous aortic or iliac surgery, 1.7–307 months before. All patients showed clinical or biochemical signs of
bleeding. Eight (53%) were in shock, five (33%) had systemic signs of infection.
Eight (53%) patients were treated in an emergency setting. Ten (67%) were treated with an aortouniiliac device, three (20%)
with an aortobiiliac device, one with a tube graft and one with occluders only. All patients received antibiotics
postoperatively for a prolonged period of time.
Results. All AEF were successfully sealed, the 30-days mortality was nil. Mean hospital stay was 20 (2–81) days. One
patient died 2.7 months later of postoperative complications, one died of lung cancer. Until now, there are no signs of
reinfection in four (27%) patients (mean follow-up 15.7 (1–44) months). However, reinfection or recurrent AEF occurred in
nine (60%) patients after 9.5 (0.61–31) months. Seven patients were reoperated successfully, two patients died after
reintervention.
Conclusion. Endovascular sealing of AEF is a promising technique, which provides time to treat shock, local and systemic
infection, and co-morbidity. This creates a better situation to perform open repair in the future with possibly better outcome.
Danger of reinfection remains high. Endovascular sealing of AEF should, therefore, be seen as a bridge to open surgery when
possible.Keywords: Aorto-enteric fistula; Endovascular treatment; Endoprosthesis.Introduction
Aorto-enteric fistula (AEF) is a severe complication
after aortic surgery and currently appears in 0.4–4%1,2
of cases after an average interval of approximately 6
years. Untreated, AEF is almost always fatal. The
widely accepted treatment is open surgery with
thorough debridement followed by either in situ
replacement of a graft or extra-anatomical reconstruc-
tion. Even in contemporary series the mortality rate
after open surgery still approximates 33%.3 Because of
the high morbidity and mortality rate of conventional
surgical treatment, the use of an aortic endoprosthesis
has been described with various outcomes.4–11 Mosting author. Dr M. Danneels, MD, Department of
Vascular Surgery, Heilig-Hartziekenhuis Roeselare-
enstraat 2, 8800 Roeselare, Belgium.
: mdanneels@hhr.be
0027+ 07 $35.00/0 q 2005 Elsevier Ltd. All rights reserreports in literature, however, are anecdotal. This
multicentre study aimed to evaluate retrospectively
the use of an aortic endoprosthesis in patients with
AEF in Belgium and The Netherlands.Patients and Methods
Between March 1999 and March 2005, 15 patients in
five university and teaching hospitals were treated
endovascularly for AEF. The data for this study were
collected from patient files in the cooperating centres
as listed in Addendum. A structured file was
completed for each patient containing the main
clinical, diagnostic and surgical parameters. The
outcome in terms of morbidity, mortality, reinfection
or recurrence of AEF was analysed. Data analysis was
performed using GraphPad Prism version 3.00 forEur J Vasc Endovasc Surg 32, 27–33 (2006)
doi:10.1016/j.ejvs.2005.11.031, available online at http://www.sciencedirect.com onved.
Table 1. Cardiovascular risk factors
Cardiovascular risk factors
Arterial hypertension 10 patients (67%)
History of smoking 10 patients (67%)
Coronary artery disease 6 patients (40%)
Hyperlipidaemia 5 patients (33%)
Diabetes mellitus 1 patient (7%)
M. I. L. Danneels et al.28Windows (GraphPad Software, San Diego, CA, USA).
The male:female ratio was 12:3. The mean age at the
moment of diagnosis was 67 (43–82) years. The
cardiovascular risk factors are summarized in Table 1.
Thirteen patients (87%) developed a secondary AEF
with a mean interval of 77 (1.7–307) months after aortic
or iliac surgery. The secondary AEF developed after
elective primary aortic surgery in eight (53%) patients
with a mean interval of 110 (42–307) months and after
emergency treatment for ruptured abdominal aortic
aneurysm in one patient (interval 60 months). The AEF
developed after previous surgery for infected aortic
grafts in four (27%) patients with a mean interval of 11
(1.7–35) months. One primary AEF was probably
caused by tuberculous aortitis, for the other primary
AEF no cause could be determined. Twelve patients
(80%) had previous abdominal surgery for non-
vascular reasons. The relevant patient history is
summarized in Table 2.
At presentation, all patients showed clinical or
biochemical signs of bleeding. Eight patients (53%)
presented with haematemesis, eight (53%) presented
with melena and seven (47%) with anal blood loss.
Five patients showed two of these signs, two patients
showed haematemesis, melena and anal blood loss.
Eight patients (53%) were in haemodynamic shock at
presentation. Eleven (73%) patients complained of
abdominal pain. Five patients (33%) had systemic
signs of infection, of which four also had abdominal
pain.
Eleven (73%) patients were anaemic at admission
(haemoglobin %11.5 g/dL). The white cell count was
elevated (R107/L) in eleven (73%) patients. C-reactive
protein level was elevated in eight out of eleven
measurements (72%). Only one patient had both a
normal white cell count and a normal C-reactive
protein level.
To confirm the diagnosis CT-scan was performed in
thirteen patients. All CT-scans performed were
suspect for AEF: there were no false-negatives.
Esophagogastroduodenoscopy (EGD) was performed
in 10 patients. Seven (70%) EGD procedures were
positive or suspect for AEF, three (30%) were negative.
One rectoscopy was performed and showed a
pulsating mass. One arteriogram was performed,
which showed no bleeding sites. In our study noEur J Vasc Endovasc Surg Vol 32, July 2006leukocyte- or PET-scans were performed to confirm
diagnosis.
All eight patients presenting with shock were
treated in an emergency setting (within 6 h after
admission). Because of severe haemodynamic shock
with systolic pressure of 40 mmHg in the intensive
care unit, one patient was stabilized using an aortic
occluding balloon at the presumed level of the AEF
before transport to the operating theatre.
All procedures were performed under general
anaesthesia, although in one patient, the groin incision
and deployment of the endoprosthesis were per-
formed under local anaesthesia and general anaes-
thesia was started afterwards for placement of the
femorofemoral crossover graft. Access was through
standard cut down of the groins in 13 patients. One
patient had a retroperitoneal approach to the iliac
artery, one patient had a temporary conduit on the iliac
axis for access.
Nine patients (60%) were treated with an aorto-
niiliac device. Seven of these patients also had an
adjunctive femorofemoral crossover graft in the same
procedure. The two other patients already had a
femorofemoral crossover graft placed before. One of
these patients also had a distal thrombectomy. Four
patients (27%) were treated with an aortobiiliac
device. One patient was treated with a tube graft
only. Another patient was treated with two occluders
and gentamycin sponges at the level of the AEF and a
right axillofemoral bypass graft with distal anasto-
mosis on a pre-existing femorofemoral crossover
graft.
Two (13%) patients were treated with a staged,
hybrid approach. In one patient, haemodynamic
stabilization was achieved by division of the AEF
and direct suture of both aorta and duodenum. Four
days later, an aortic tube device was placed because
the surgeon felt the direct suture of the aorta was
insufficient. Another patient was treated with an
aortobiiliac device for haemodynamic stabilization.
Three days later, a second procedure was performed
with resection of the fistula, partial resection of the
jejunum and omentoplasty. The endoprosthesis was
not removed.
Ten patients (66.7%) were treated with a Talent
device (Medtronic Inc., Minneapolis, MN, USA), four
patients (27%) were treated with a Zenith Tri-Fab
device (Cook Inc., Bloomington, IN, USA), one patient
was treated with a Vanguard device (Boston Scientific
Co., Natick, MA, USA)
In the two hybrid procedures it was possible to
obtain local microbiology cultures that revealed
Citrobacter Freundii in one patient and both Enterobacter
sp. and Bacteroides sp. in the other patient.
Table 2. Patient history, treatment and postoperative follow-up in 17 patients treated with endoprosthesis for AEF
History Treatment Follow-up
Patient A, M,
49 years
Multiple aneurysms, AIG for infrarenal AAA 5
years before, arterial homograft AIG for aorto-
enteric erosion 3 years before, aneurx endoprosth-
esis for pseudo-aneurysm on the proximal anasto-
mosis 6.1 months before, open cholecystectomy,
protein S deficiency, lumbar sympathectomy
Aortomonoiliac deviceCfemorofemoral cross-over
graft, meropenem for 3 weeks; clindamycin life long
3.2 months postoperative: septic emboli due to
recurrence of AEF, treatment: right axilloiliac and
hepatorenal bypass in first stage; left aortorenal and
aortomesenteric bypassCresection of endoprosth-
esis in second stage, complications: renal insuffi-
ciency, pneumonia, pulmonary haematoma, 7.2
months postoperative: ok
Patient B, M,
71 years
AFG for Leriche’s syndrome 12 years before,
irresectable lung carcinoma
Aortobiiliac device, gentamycin/metronidazol/
penicillin for 2 weeks
Died of lung carcinoma
Patient C, M,
76 years
AFG for Leriche’s syndrome 26 years before, 1975:
open cholecystectomy, 1965: gastrectomy (benign
ulcer), adhesiolysis
Aortomonoiliac deviceCfemorofemoral cross-over
graft, meropenem for 3 weeks; levofloxacin/
metronidazole lifelong
6.1 months postoperative: back pain and infectious
blood results due to recurrence AEF at duodenum,
treatment: bilateral axillofemoral graft and resection
of endoprosthesis, complications: myocardial
infarction, pneumonia, 21 months postoperative: ok
Patient D, M,
59 years
Thrombolysis and stenting iliac axis for aortic
thrombosis, miliary tuberculosis, billroth II gas-
trectomy, ostial left renal artery stenosis
Aortomonoiliac deviceCfemorofemoral cross-over
graft, teicoplanin/fluconazole for 41 days; merope-
nem/vancomycin for 7 days
Died 81 days postoperative (multiple organ failure)
Patient E, M,
72 years
Left below knee amputation for osteomyelitis,
claudication right leg, AFG 4 years before, appen-
dectomy
Aortobiiliac device, 2 days later wedge excision of
jejunal fistulaComentoplasty, amoxicillin/clavula-
nate/fluconazole for 4 days; co-trimoxazole lifelong
7.5 months postoperative: ok
Patient F, M,
70 years
Thrombosis of popliteal aneurysm, cystectomy and
bricker derivation, low grade infection groin,
adhesiolysis, AFG for rupturing AAA 5 years before
Aortomonoiliac deviceCfemorofemoral cross-over
graft, amoxicillin/clavulanate for 19 days; doxycy-
clin lifelong
2.8 months postoperative: abscess right groin (E.
Coli and S. Viridans), treatment: surgical drainageC
antibiotics, 5 months postoperative: ok
Patient G, M,
73 years
Bilateral lumbar sympathectomy, AFG for Leriche’s
syndrome 16 years before, AEF treated with closure
of fistula and omentoplasty 1.67 months before,
open cholecystectomy, ischaemic colitis
Aortobiiliac device, piperacillin/tazobactam for
8 days; co-trimoxazole life long
31 months postoperative: recurrence of AEF
between jejunum and right graft limb, treatment:
suture of right graft limb, closure of jejunum,
omentoplasty, 10 days later: new AEF between
duodenum and proximal aorta, treatment: closure
of duodenum, rectus abdominis muscle flap, 1 week
later excision of prosthetic graft, AFG arterial
homograft, bilateral aortorenal bypass, died of
sepsis and multiple organ failure 33 months post-
operative
Patient H, F,
77 years
Coronary artery bypass grafts 10 days before Aortomonoiliac deviceCfemorofemoral cross-over
graftCdistal thrombectomy, gentamycin for
10 days; amoxillin/clavulanate life long
9 months postoperative abscess in left psoas muscle
and recurrence of AEF with infected endoprosth-
esis, treatment: excision of endoprosthesis and
prosthetic graft, silver impregnated right aortoiliac
graft, closure of jejunum, omentoplasty, 23 months
postoperative: ok
Patient I M,
47 years
Left renal artery dilation, AFG for Leriche’s
syndrome 10 years before, femorofemoral crossover
graft right to left, left iliofemoral graft, left
supragenual femoropopliteal graft, excision
infected crossover graft 7 years before, left aorto-
popliteal graft 1 year before, hartmann procedure
after intestinal perforation during aortopopliteal
grafting, excision infected iliofemoral graftCclo-
sure enterocutaneous fistula 2.23 months before
Temporary sealing of fistula with aortic balloon,
proximal and distal occluders with gentamycin
sponge in between, right axillofemoral bypass,
antibiotic treatment: not specified, life long
10.3 months postoperative: ok
(continued on next page)
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Table 2 Continued
History Treatment Follow-up
Patient J, M,
61 years
Tube interposition from celiac trunk to aortic
bifurcation for type IV thoracoabdominal aneurysm
7 years before, osteosynthesis for discitis L3–L4
Aortobiiliac device, extraction of loose pedicle
screw, ciprofloxacin life long
0.6 months postoperative: acute arterial blood loss
in left groin, treatment: left aortomonoiliac endo-
prosthesis, femorofemoral silver impregnated
crossover graft, excision of migrated osteosynthesis
material between inferior caval vein and prosthesis,
1.4 months postoperative: ok
Patient K, M,
78 years
AIG for AAA 4 years before Open division of aortoenteric fistula, 4 days later
sealing with endovascular tube graft device,
gentamycin/cefuroxim/metronidazole for 4 weeks;
amoxicillin/clavulanate for 2 weeks; co-trimoxazole
for 4 months
44 months postoperative: ok
Patient L, M,
75 years
AIG for AAA 11 years before Aortomonoiliac deviceCfemorofemoral cross-over
graft, gentamycin for 7 days; amoxicillin/clavula-
nate life long
12 months postoperative: recurrence of AEF
(actinomycesCbacteroides), treatment: resection of
all infected prosthetic grafts, left aortoiliac pros-
thetic graft (rifamicyn soaked), closure of two
duodenal perforations, omentoplasty, 20 months
postoperative: ok
Patient M, M,
81 years
Tube interposition for AAA 8 years before, barrett
oesophagitis and duodenitis, Transvesical prosta-
tectomy, diverticulosis, polycystic kidney disease,
chronic obstructive lung disease, atrial fibrillation
Aortomonoiliac deviceCfemorofemoral cross-over
graft, piperacillin/tazobactam for 7 days; amox-
icillin/clavulanate life long
1 month postoperative: ok
Patient N, F,
73 years
Stenting left renal artery, AFG for Leriche’s syn-
drome 5 years before, axillobifemoral graft for
occluded AFG 4 years before, appendectomy and
drainage of psoas abscess
Aortomonoiliac device, amoxicillin/clavulanate life
long
12 months postoperative: recurrence of AEF,
treatment: excision of endoprosthesis, prosthetic
patch on aorta, closure of duodenal lesion, 2 days
later: haemodynamic shock, new bleeding, further
treatment refused by patient, patient died 12.03
months postoperative
Patient O, F,
43 years
Extraperitoneal aortoiliac disobliteration according
to LeVeen,16 endarterectomy and patch of the
infrarenal aorta, AIG for occlusion after endarter-
ectomy, suture and femorofemoral cross-over graft
for ruptured distal false aneurysm caused by
appendicitis 3 years before, draining of abscesses in
right groin, retroperitoneal, etc.
Aortomonoiliac device, amoxicillin/clavulanate life
long
8.7 months postoperative: abscess in rectovesical
excavation (Douglas’ pouch), treatment: CT-guided
puncture, 9.5 months postoperative: ok
AAA, abdominal aorta aneurysm; AFG, aortobifemoral bypass graft; AIG, aortobiiliac bypass graft; F, female; M, male; where time interval is mentioned, always between event and
endovascular treatment of AEF.
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Endovascular Repair for Aorto-enteric Fistula 31All patients received antibiotics postoperatively for
at least 14 days according to the empirical guidelines
from the departments of microbiology of the various
co-operating hospitals. Four patients were treated
with antibiotics for a period between 6 weeks and 9
months. At discharge from the hospital, eight patients
were prescribed life long antibiotic treatment.Results
All AEF were successfully sealed. The 30-days
mortality was nil. Mean intensive care stay was 6.7
(0–61) days. Mean hospital stay was 20 (2–81) days. Six
patients (40%) had no postoperative complications. All
postoperative complications and reinterventions in
nine patients (60%) are summarized in Table 3. The in-
hospital mortality was 7%: one patient with infectious,
vascular, and cardiac complications died on the 81st
postoperative day.
Another patient died of lung cancer within the first
postoperative year. Four (50%) out of eight patients
with life long antibiotics stopped the treatment: three
because of serious antibiotic related gastrointestinal
complaints, one patient stopped without apparent
reason.
Until now, there are no signs of recurrent infection
or AEF in four out of 13 (31%) patients, including the
two patients who had a hybrid procedure. The mean
follow-up in these four patients is 16 (1–44) months.
Reinfection occurred in nine (69%) patients after a
mean interval of 9.5 (0.6–31) months. Two thirds of
these nine patients had a new AEF. The symptoms,
treatment and outcome of these patients are summar-
ized in Table 2.
All patients were reoperated on successfully. One
patient had recurrent bleeding some days after
reintervention. She refused all surgical treatment andTable 3. Postoperative complications after endovascular treatment fo
Postoperative complications
Renal (four patients) Chronic renal insufficiency: thr
Acute renal insufficiency
Gastro-intestinal (three patients) Duodenal necrosis and perfora
Subobstruction treated conserv
Choledocholithiasis treated con
Infectious (three patients) Catheter sepsis with MRSE
Postoperative bacteraemia
Groin abscess, treated by surgi
Pulmonary (two patients) Exacerbation of chronic obstru
Tracheotomy for difficult posto
Cardiac (two patients) Pulmonary oedema
Myocardial infarction on posto
Vascular (one patient) Hepatorenal shunt 26 days pos
Puncture through femorofemo
patient)died 2 days after diagnosis of the recurrent bleeding.
One patient developedmultiple organ failure and died
2 months after reoperation. Until now, the other
patients have an uneventful course after reoperation
with a mean follow-up of 16 (1–44) months.
During the follow-up period no dislocation or
endoleak of the grafts have been observed.
Kaplan–Meier analysis showed an overall survival
of 92% at 6 months, the 95% confidence interval (CI) is
78–100%. At 1 year the survival is 79% (CI 52–100%), at
2 years the survival is 66% (CI 33–98%) as shown in
Fig. 1. The freedom of recurrence of AEF is 65% (CI 40–
90%) at 6 months. At 1 and 2 years the freedom of
recurrence is 29% (CI 3–55%) as shown in Fig. 2.Discussion
AEF is the most serious late complication of aortic
graft placement and occurs in 0.4–4%.1,2 According to
Busutill et al.3 the mean interval between initial
surgery and diagnosis of AEF is approximately 6
years, although it has been described as early as 2
weeks after aortic surgery. It is caused by erosion of the
gastro-intestinal tract by the prosthetic graft, with or
without formation of a false aneurysm. Menawat
et al.12 found that AEF seems more frequent after
surgery for aorto-iliac occlusive disease than after
aneurysmal disease. In this retrospective study, we
were not able to confirm these findings, due to the
small number of patients. Most patients had aortic
surgery in their medical history. This is consistent with
literature findings.13 Four patients (27%) already had
aortic reinterventions because of a previous AEF or
infected aortic graft. One of these patients already had
an endoprosthesis for a false aneurysm on an arterial
homograft. The interval between previous aortic
surgery and the clinical presentation of an AEF wasr AEF
ee patients, of which one patient started haemodialysis 3 years later
tion, treated by surgical drainage on postoperative day 51
atively
servatively
cal drainage on postoperative day 13
ctive lung disease necessitating reintubation
perative weaning
perative day 7, followed by pulmonary oedema
toperative for right renal artery stenosis
ral cross over graft during drainage of an abdominal mass (same
Eur J Vasc Endovasc Surg Vol 32, July 2006
Fig. 1. Kaplan–Meier analysis including confidence interval: overall survival.
M. I. L. Danneels et al.32significantly shorter in this subgroup compared to
patients without reinterventions on the aorta (pZ0.01).
In every patient with clinical evidence of infection
or bleeding of the gastrointestinal tract after aortic
surgery, AEF should always be suspected. According
to the classic triad of symptoms in AEF, all our
patients had one or more signs of gastrointestinal
bleeding (haematemesis, melena, haematochezia,
anaemia). One in three had clinical symptoms of
infection. All but one patient had biochemical signs of
infection and all had various abdominal complaints.
One third of the patients were in shock at presen-
tation at the emergency ward or at transfer from
another hospital.
In case of severe haemodynamic shock, prompt
treatment should be undertaken. In less urgent
situations, a CT-scan followed by EGD can be
performed to rule out other causes of disease.
However, a negative result does not exclude AEF. In
our series every abdominal CT-scan performed was
positive or suspect for AEF. EGD was positive orFig. 2. Kaplan–Meier analysis including confidence in
Eur J Vasc Endovasc Surg Vol 32, July 2006suspect in 70%. One preoperative angiography was
performed and was negative.
Taking in account the high co-morbidity, previous
laparotomies and/or shock at presentation, the risk of
conventional repair was considered too high in this
patient group. Although various mortality rates can be
found in literature, mortality after conventional repair
for AEF is now considered to be approximately 33%
with a high co-morbidity.3,14 In our series the total
AEF-related mortality is 20%, of which two thirds
occurred following reintervention at the moment of
recurrent infection or new AEF.
In the postoperative care, antibiotic treatment is of
the uttermost importance. In contrast to conventional
repair, it is not always possible to obtain a good sample
of the infectious agent. Consequently, antibiotic
and/or antifungal treatment remains empirical. On
the other hand, infected prosthetic material is not
resected. This probably maintains a subclinical
infectious process. One can expect a high rate of
recurrent infection when the antibiotic spectrum is notterval: freedom of recurrent infection or new AEF.
Endovascular Repair for Aorto-enteric Fistula 33adequately chosen or when the treatment is stopped
early. This emphasizes the need for prolonged
antibiotic treatment, preferably lifelong. Our study
revealed, however, that half of the patients stopped
their ‘lifelong’ treatment after a while, mostly because
of a (presumed) gastrointestinal intolerance.
Several case reports with good long-term outcome
can be found in the literature.7,8,10 Burks et al.15
reported three patients with persistent postoperative
sepsis after EVAR, but no recurrence of AEF in a group
of seven patients (follow-up 11–67 months). However,
in our series seventy percent of all patients had a
recurrent infection or new AEF within 1 year, even
with adequate antibiotic treatment. Due to the high
recurrence rate in our series, we feel that resection of
the infected prosthesis, debridement and extra-ana-
tomical or in situ revascularisation remains the
treatment of choice for patients without shock and in
fair general condition at the moment of presentation.
Every patient with an AEFwith a high operative risk
for open surgery should be considered for endovascular
treatment. We think the high reinfection rate justifies
open repair as soon as the patient’s risk factors are
reduced to a minimum.We now believe surgery should
be performed before recurrent infection or newAEF has
become apparent. This avoids the extra risk of an urgent
or semi-urgent open procedure in an infectious and/or
haemodynamically unstable patient.
Endovascular treatment of AEF should, therefore, be
seen as a short bridge to surgery, except for patients
remaining unfit for open surgery even after maximal
supportive therapy. In those patients, long-term anti-
biotic treatmentand lifelongsurveillancearemandatory.5. Addendum
The participating centres were:
Ghent University Hospital (four patients)
University Medical Center Utrecht (four patients)
Atrium Medical Center Heerlen (three patients)
Leuven University Hospitals (three patients)
Catharina Hospital Eindhoven (one patient).References
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